Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nesvacumab
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intravitreal
01
Overview
Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds to and inhibits angiopoietin-2 (Ang2), a ligand for the TEK tyrosine kinase receptor (Tie2). By blocking Ang2, nesvacumab interferes with the Ang2-Tie2 interaction, thereby inhibiting angiogenesis and tumor cell proliferation. It was originally developed for cancer treatment but has also been investigated in ophthalmology for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Clinical trials have shown that while nesvacumab can reduce central retinal thickness in DME, its combination with aflibercept did not provide additional visual acuity benefit over aflibercept monotherapy. Nesvacumab was developed by Regeneron Pharmaceuticals and Sanofi[1][3][4][5].
- Other names
- Ang2 antibody - Regeneron PharmaceuticalsAng-2 antibody - Regeneron PharmaceuticalsAng 2 antibody - Regeneron Pharmaceuticals
02
Targets
ANGPT2 (Angiopoietin-2)
Beyond the preview
Go deeper on nesvacumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nesvacumab.